Answers are grounded in this paper and cite their sources.
Review highlights IL-18's impact on atopic dermatitis severity and immune responses in patients, suggesting therapeutic potential.
Atopic dermatitis (AD) is a common chronic inflammatory skin disease characterized by pruritus, barrier dysfunction and immune cell infiltration. Despite significant progress in our understanding of AD pathophysiology, the molecular mechanisms driving the disease remain only partially elucidated. Recently, the cytokine IL-18, a member of the IL-1 family, has drawn attention for its involvement in diverse immune responses and potential impact on disease severity. In this review, we examine the role of IL-18 in AD, with a focus on genetic associations, biomarker potential, and cellular sources. Elevated IL-18 levels in both the skin and serum of AD patients are positively correlated with disease severity, type 2 immune response and impaired barrier function. Mouse models of AD reinforce the importance of IL-18, where neutralization or genetic knockout alleviates AD-like features. We further explore how IL-18 drives type 2 immune responses in the skin and the cellular mechanisms involved. Collectively, current literature supports a crucial role for IL-18 in AD pathophysiology, indicating that targeting IL-18 may be a promising therapeutic strategy for managing the disease.
No takes yet. Share an insight, caveat, or question.
Bähler et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: